Osman, E. Y.
Rietz, A.
Kline, R. A.
Cherry, J. J.
Hodgetts, K. J.
Lorson, C. L.
Androphy, E. J.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01HD064850, R21NS064349, R21HD057402, R01HD064850, R21NS064349, R21HD057402)
CureSMA, FightSMA, Gwendolyn Strong Foundation
Article History
Received: 25 October 2018
Accepted: 20 December 2018
First Online: 7 February 2019
Competing Interests
: CLL is the co-founder and Chief Scientific Officer of Shift Pharmaceuticals.